Physician profile
Luis A Concepcion
NPI 1194778449
$3,500.47
in general payments reported to CMS, 2019-2025
46 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $192 · 2021: $660 · 2022: $158 · 2023: $377 · 2024: $478 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100 · Education: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.03 |
| Education | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $350.05 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $350.02 | 2019-2025 | |
| Astellas Pharma US INC | $249.93 | 2019-2024 | Xtandi |
| Astrazeneca Pharmaceuticals LP | $181.21 | 2019-2023 | Imfinzi |
| Janssen Biotech, INC. | $174.71 | 2019-2023 | Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $147.39 | 2019-2024 | Enhertu |
| Merck Sharp & Dohme LLC | $132.61 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $121.76 | 2019-2025 | Opdualag, Augtyro |
| Celgene Corporation | $120.96 | 2021-2025 | Reblozyl, Pomalyst |
| Seagen INC. | $109.02 | 2021-2023 | Tukysa |
| Amgen INC. | $98.34 | 2019-2022 | |
| Gilead Sciences, INC. | $86.74 | 2022-2024 | |
| Genentech USA, INC. | $84.82 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $83.78 | 2019-2023 | Imbruvica |
| Genzyme Corporation | $79.67 | 2019-2024 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Concepcion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.